His work focuses on how microbial ecosystems interact with human physiology, including: Gut barrier function and intestinal permeability Mucus-associated microbiota (Akkermansia-related systems) Oralgut microbiome axis Short-chain fatty acids (SCFAs) and metabolic signaling Circadian rhythmmicrobiome interactions Clinical Research Contributions He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including: Active Ulcerative Colitis (Inflammatory Bowel Disease) Hyperoxaluria (Oxalate Metabolism Disorder) Microbiome-driven gut health and inflammatory conditions These studies were part of broader clinical development programs evaluating microbiome-based approaches
Tufik S, Santos-Silva R, Taddei JA, Bittencourt LR
In vitro, animal, and clinical research suggest that trimethoprim inhibits intestinal thiamine transporter ThTR-2, hepatic transporter OCT1, and renal transporters OCT2, MATE1, and MATE2, resulting in paradoxically increased thiamine plasma concentrations
What gets consumed is different